Clinical trial
Combination Casodex® and Iressa™ in Locally Advanced Prostate Cancer
NCT00319787 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00319787 |
|---|---|
| Title | Combination Casodex® and Iressa™ in Locally Advanced Prostate Cancer |
| Official title | A Randomized Placebo Controlled Study to Assess the Rate of PSA Decrease, Anatomical & Metabolic Changes in the Prostate Determined by MRI/3D-MRS & Histological Changes by Biopsy in Subjects With Locally Advanced Prostate Carcinoma Treated With Either Casodex® (Bicalutamide) Alone or the Combination… |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Locally Advanced Prostate Cancer |
| Intervention type | Drug |
| Interventions | Iressa |
| Enrollment | 102 |
| Start date | Dec 1, 2003 |
| Completion | Aug 1, 2006 |
| First posted | Apr 27, 2006 |
| Last update posted | Jan 25, 2011 |
| Countries | Norway |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: